Tag: PD-L1
-
Immunotherapy Advances in SCLC: Promise, Limitations, and Biomarker Needs
Overview: Immunotherapy’s Emerging Role in SCLC Small cell lung cancer (SCLC) has long challenged clinicians with its aggressive biology and tendency for rapid relapse. In recent years, immunotherapy has emerged as a beacon of hope, offering meaningful efficacy gains in several lines of treatment. This article reviews the current state of immunotherapy in SCLC, highlighting…
-
Pembrolizumab Doubles Survival in Advanced Head and Neck Cancer
The Breakthrough: A New Immunotherapy Redefines Outcomes in Locally Advanced Head and Neck Cancer Locally advanced head and neck cancer poses a formidable challenge. In many patients, the disease is detected at a stage where surgery, radiotherapy, and chemotherapy are the mainstays of treatment, yet recurrence and progression remain common. A recent advance in immunotherapy,…